<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="219469">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226941</url>
  </required_header>
  <id_info>
    <org_study_id>COR0001</org_study_id>
    <secondary_id>95054</secondary_id>
    <secondary_id>COR0001</secondary_id>
    <nct_id>NCT00226941</nct_id>
  </id_info>
  <brief_title>Safety Study of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer</brief_title>
  <official_title>A Phase I/II Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgical Resection for Locally-Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Albert Fisher</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      1. To determine the MTD and DLTs of oxaliplatin and capecitabine when combined with C225
           and radiotherapy (Phase I)

        2. To determine the pathologic response rate of C225 in combination with this neoadjuvant
           cytotoxic regimen (Phase II)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the MTD and DLTs of oxaliplatin and capecitabine when combined with C225 and radiotherapy (Phase I)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>o determine the pathologic response rate, at the time of surgical resection, of C225 in combination with this neoadjuvant cytotoxic regimen (Phase II).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the effect of EGFR inhibition on immunohistochemical markers of downstream pathways</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine additional efficacy endpoints including downstaging, local relapse rate and survival, and time-to-progression in patients treated with the treatment regimen</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the toxicity associated with this treatment and to document perioperative morbidity.</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Colon/Rectal Cancer Rectal Cancer</condition>
  <condition>Colon/Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>first cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C225 Oxaliplatin D 2 and 23 Capecitabine XRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C225 Oxaliplatin D 2 and 23 Capecitabine XRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>third cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C225 Oxaliplatin D 2 and 23 Capecitabine XRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C225 Oxaliplatin D 2 and 23 Capecitabine XR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin is supplied as freeze-dried powder for IV infusion in vials containing 50 mg and 100 mg of the drug.</description>
    <arm_group_label>first cohort</arm_group_label>
    <arm_group_label>Second cohort</arm_group_label>
    <arm_group_label>third cohort</arm_group_label>
    <arm_group_label>cohort -1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>The calculated dose by cohort designation and body surface area (BSA) will be rounded down to allow equivalent morning and evening doses using a combination of 150 mg and 500 mg tablets.</description>
    <arm_group_label>first cohort</arm_group_label>
    <arm_group_label>Second cohort</arm_group_label>
    <arm_group_label>third cohort</arm_group_label>
    <arm_group_label>cohort -1</arm_group_label>
    <other_name>C225</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab may be administered via a gravity drip, infusion pump or syringe pump with in-line filtration. Cetuximab requires in-line filtration during administration. Calculate and draw the appropriate volume of cetuximab into a sterile syringe based on either the 400 mg/m2 initial dose or 250 mg/m2 weekly dose</description>
    <arm_group_label>first cohort</arm_group_label>
    <arm_group_label>Second cohort</arm_group_label>
    <arm_group_label>third cohort</arm_group_label>
    <arm_group_label>cohort -1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:- Patients with histologically confirmed adenocarcinoma of the rectum:
        EUS stage T3 or T4 or N1 disease are eligible (includes T3 N0, T3 N1, T4 N0, T4 N1, T1-4
        N1). Rectal cancers will be defined as those whose distal border extends to within 12cm of
        the anal verge.

          -  Age &gt;= 18.

          -  Karnofsky performance status &gt;= 70.

          -  Creatinine within normal institutional limits or creatinine clearance &gt;
             60mL/min/1.73m2 for patients with serum creatinine levels above institutional normal.

          -  Negative urine pregnancy test if a woman of child bearing potential (WOCBP).

          -  WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L
             or equivalent units of HCG) within 72 hours prior to the start of study medication.

          -  WOCBP must be using an adequate method of contraception to avoid pregnancy throughout
             the treatment.

          -  Ability to swallow pills without difficulty.

          -  No prior pelvic or whole abdominal radiotherapy.

          -  Patients must have adequate organ and marrow function as defined below:

        Leukocyte count &gt; 3,500. Platelet count &gt; 100,000. SGOT, SGPT, Alk. Phos: &lt; 2.5x
        institutional upper limits of normal. Total bilirubin &lt; 1.5x institutional normal
        institutional limits.

        Exclusion Criteria:- Metastatic (M1) or stage IV disease.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Patients with a concurrent malignancy or previous malignancy within 5 years of
             screening will be excluded from this study; with the exception of patients with
             concurrent or previous non-melanoma skin cancer, hematolymphoid malignancy or
             carcinoma in-situ of the cervix, who may be included at the investigator's
             discretion.

          -  WOCBP who is pregnant or breastfeeding.

          -  A history of C225 or other therapy that targeted the EGF receptor.

          -  A history of prior anti-cancer murine monoclonal antibody therapy.

          -  Inability to sign written consent.

          -  WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for
             the entire study period and for up to 4 weeks after the study. Subjects who are men
             must also agree to use effective contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Branimir I Sikic</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Albert Fisher M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <lastchanged_date>November 6, 2012</lastchanged_date>
  <firstreceived_date>September 8, 2005</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>George Albert Fisher</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
